Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
31188728
Public Release Type:
Journal
Publication Year: 2019
Affiliation: Center for Personalized Cancer Therapy, University of Massachusetts, Boston, Massachusetts.; George M. O'Brien Center for Benign Urologic Research, University of Wisconsin, Madison, Wisconsin.; Department of Urology, University of Wisconsin, Madison, Wisconsin.; Department of Urology, Loyola University Medical Center, Maywood, Illinois.; George M. O'Brien Center for Benign Urologic Research, University of Wisconsin, Madison, Wisconsin.
DOI:
https://doi.org/10.1097/JU.0000000000000385
Authors:
Macoska Jill A, Uchtmann Kristen S, Leverson Glen E, McVary Kevin T, Ricke William A
Request IDs:
20150
,
20877
,
21725
Studies:
Medical Therapy of Prostatic Symptoms
Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men. Recently fibrosis has been implicated as another pathobiology contributing to male lower urinary tract symptoms but to our knowledge no systematic studies have been done to assess fibrosis in the context of medical treatment. We determine whether fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in participants treated with doxazosin, finasteride or finasteride plus doxazosin in the MTOPS (Medical Therapy of Prostatic Symptoms) study.
